Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Programmed death ligand 1 (PD-L1) plays a role in tumor development and spread.
• PD-L1 expression on tumor cells is implicated in various cancers, including lung and breast carcinomas.
• Understanding PD-L1 expression in sarcomas is crucial for potential targeted therapies.

Purpose of the Study:

• To investigate the prevalence and patterns of PD-L1 expression in a diverse range of sarcoma types.
• To analyze PD-L1 expression at both the protein and mRNA levels in sarcomas.
• To identify specific sarcoma subtypes with higher PD-L1 expression for further research.

Main Methods:

• Retrospective analysis of 222 sarcoma tissue microarrays.
• Immunohistochemical staining for PD-L1 antibody, with membranous staining >5% considered positive.
• Quantitative real-time PCR for PD-L1 mRNA expression in PD-L1 positive cases.

Main Results:

• PD-L1 protein expression was detected in 34 of 222 (15%) sarcomas.
• Higher PD-L1 expression frequencies were observed in undifferentiated pleomorphic sarcomas (39%), malignant peripheral nerve sheath tumors (33%), and dedifferentiated liposarcomas (31%).
• PD-L1 mRNA overexpression was found in 47% of immunohistochemically positive cases, often at low levels.

Conclusions:

• PD-L1 expression occurs in a subset of sarcomas at both protein and mRNA levels.
• High-grade pleomorphic sarcomas exhibit more frequent PD-L1 expression.
• Clinical trials investigating anti-PD-L1 drugs in PD-L1 expressing sarcomas are warranted.